secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001636282-25-000091
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Q2 net loss $36.7M; cash $526.6M; initiates Phase 2 SKYLINE-UC; TL1A data positive
--------------------------------------------------------------------------------

- Net loss of $36.7M for Q2 2025 ($38.8M in Q2 2024); stock-based compensation $9.4M.
- Cash, equivalents, and marketable securities of $526.6M as of June 30, 2025; expected runway into H2 2028.
- R&D expense rose to $40.1M from $32.6M YoY on higher clinical trial costs; recognized $10.0M gain on sale of legacy asset pegzilarginase.
- Positive interim Phase 1 data for two anti-TL1A antibodies (SPY002/SPY072): well-tolerated, PK supports Q3M/Q6M dosing, full TL1A engagement to 20 weeks.
- Initiated Phase 2 SKYLINE-UC platform in May; on track to start Phase 2 SKYWAY-RD basket study in Q3 2025; SPY003 Phase 1 data expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/0001636282-25-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/syre-20250805.htm
  HTML page:      https://secwatch.observer/filing/0001636282-25-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer